When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Axicabtagene ciloleucel - Wikipedia

   en.wikipedia.org/wiki/Axicabtagene_ciloleucel

   Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. [8] T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor .

3. Kite Pharma - Wikipedia

   en.wikipedia.org/wiki/Kite_Pharma

   It garnered a US FDA Breakthrough Therapy Designation (Dec 2015) for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). [12] It was approved for use in the United States under the brand name YESCARTA in October 2017. [3]

4. Gilead’s Kite Receives FDA Approval For Yescarta ... - AOL

   www.aol.com/news/gilead-kite-receives-fda...

   Kite, a unit of Gilead Sciences, announced that the US Food and Drug Administration (FDA) has approved its Yescarta T cell immunotherapy. The therapy is a first-of-its-kind treatment for adult ...

5. Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA ... - AOL

   www.aol.com/news/gileads-gild-car-t-cell...

   Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

6. CAR T cell - Wikipedia

   en.wikipedia.org/wiki/CAR_T_cell

   These trials ultimately led in the US to the FDA's first two approvals of CAR T cells in 2017, those for tisagenlecleucel (Kymriah), marketed by Novartis originally for B-cell precursor acute lymphoblastic leukemia (B-ALL), and axicabtagene ciloleucel (Yescarta), marketed by Kite Pharma originally for diffuse large B-cell lymphoma (DLBCL). [15]

7. FDA investigating risk of secondary cancers after CAR-T ... - AOL

   www.aol.com/news/fda-investigating-risk...

   Currently approved products in that class include Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta, according to the announcement. ... the first CAR-T cancer therapy approved by the FDA ...